356 related articles for article (PubMed ID: 29305415)
1. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
3. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
4. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
[TBL] [Abstract][Full Text] [Related]
6. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
[TBL] [Abstract][Full Text] [Related]
7. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
9. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
Li YY; Wang YF; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
[TBL] [Abstract][Full Text] [Related]
10. Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.
Jiang T; Wang F; Hu L; Cheng X; Zheng Y; Liu T; Jia Y
Oncotarget; 2017 Sep; 8(44):77586-77594. PubMed ID: 29100410
[TBL] [Abstract][Full Text] [Related]
11. A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.
Fernandez-Pol S; Ma L; Joshi RP; Arber DA
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):416-422. PubMed ID: 29629950
[TBL] [Abstract][Full Text] [Related]
12. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
13. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
14. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
[TBL] [Abstract][Full Text] [Related]
15. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
Zhang H; Dong L; Chen Q; Kong L; Meng B; Wang H; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X
Leuk Res; 2017 May; 56():29-35. PubMed ID: 28171799
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.
Laginestra MA; Cascione L; Motta G; Fuligni F; Agostinelli C; Rossi M; Sapienza MR; Righi S; Broccoli A; Indio V; Melle F; Tabanelli V; Calleri A; Novero D; Facchetti F; Inghirami G; Sabattini E; Bertoni F; Pileri SA
Mod Pathol; 2020 Feb; 33(2):179-187. PubMed ID: 31028364
[TBL] [Abstract][Full Text] [Related]
18. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells.
Zhang W; Shen H; Zhang Y; Wang W; Hu S; Zou D; Zhou D
Cancer Med; 2019 May; 8(5):2104-2113. PubMed ID: 30969023
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
Front Immunol; 2022; 13():835103. PubMed ID: 35185926
[TBL] [Abstract][Full Text] [Related]
20. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
